deltatrials
Unknown PHASE2 INTERVENTIONAL 1-arm NCT05254899

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage Extranodal NK/T Cell Lymphoma, Nasal Type: A Multi-center Phase II Study

Sponsor: Chinese Academy of Medical Sciences

Conditions Early-stage Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type High-Risk Cancer
Interventions Anti-PD-1 monoclonal antibody Gemcitabine Involved site radiotherapy Oxaliplatin Pegaspargase
Updated 8 times since 2022 Last updated: Feb 23, 2022 Started: Oct 1, 2021 Primary completion: Sep 30, 2022 Completion: Sep 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Early-stage and Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type and is currently ongoing. Chinese Academy of Medical Sciences leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2022 – ~Nov 2022 · 8 months · monthly snapshotRecruiting~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshotRecruiting~Dec 2022 – ~Oct 2023 · 10 months · monthly snapshotRecruiting~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshotRecruiting~Nov 2024 – ~Apr 2025 · 5 months · monthly snapshotUnknown~Apr 2025 – present · 15 months · monthly snapshotUnknown

Change History

8 versions recorded

  1. Apr 2025 — Present [monthly]

    Unknown PHASE2

  2. Nov 2024 — Apr 2025 [monthly]

    Unknown PHASE2

    Status: Recruiting → Unknown

  3. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Oct 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 3 earlier versions

  1. Dec 2022 — Oct 2023 [monthly]

    Recruiting PHASE2

  2. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  3. Mar 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chinese Academy of Medical Sciences
  • Peking University Cancer Hospital & Institute
  • The Affiliated Hospital Of Guizhou Medical University
  • The First Hospital of Jilin University
Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations